Please wait a minute...
European Journal of Gynaecological Oncology  2017, Vol. 38 Issue (6): 956-959    DOI: 10.12892/ejgo3542.2017
Case Report Previous articles | Next articles
Chemotherapy-induced hemolytic uremic syndrome in locally advanced cervical cancer treated with combination chemotherapy after laparoscopic radical hysterectomy: a case report and review of the literature
J.Y. Kwack1, H.J. Roh1, *(), S.G. You1, H.J. Cho2, S.H. Lee1, Y.S. Kwon1
1 Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea
2 Department of Obstetrics and Gynecology, University of Inje College of Medicine, Haeundae Paik Hospital, Busan, Korea
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Hemolytic uremic syndrome (HUS) is a rare complication of chemotherapy characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure without disseminated intravascular coagulation. Although few cases of chemotherapy-induced HUS have been reported in gynecologic malignancy, it can be a fulminant, chronic disease and can be managed with early aggressive treatment. A 38-year-old woman was diagnosed with FIGO Stage IIb squamous cell carcinoma of the uterine cervix. After three cycles of neoadjuvant chemotherapy that consisted of a combined regimen of mytomicin-C, vincristine, and cisplatin, a laparoscopic radical hysterectomy was performed, and the pathological diagnosis of the residual lesion was deep stromal invasion. Following two adjuvant courses of the same chemotherapy, she developed chemotherapy-induced HUS. The patient was aggressively treated with therapeutic plasma exchange with fresh-frozen plasma and a high dose of steroids. At the last follow-up, the serum creatinine level had decreased to 1.81 mg/dl, and evidence of recurrence was not found.
Key words:  Hemolytic uremic syndrome      Mitomycin-C      Neoadjuvant chemotherapy      Therapeutic plasma exchange      Cervical cancer     
Published:  10 December 2017     
*Corresponding Author(s):  H.J. ROH     E-mail:  dr-nhj@hanmail.net

Cite this article: 

J.Y. Kwack, H.J. Roh, S.G. You, H.J. Cho, S.H. Lee, Y.S. Kwon. Chemotherapy-induced hemolytic uremic syndrome in locally advanced cervical cancer treated with combination chemotherapy after laparoscopic radical hysterectomy: a case report and review of the literature. European Journal of Gynaecological Oncology, 2017, 38(6): 956-959.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3542.2017     OR     https://ejgo.imrpress.com/EN/Y2017/V38/I6/956

[1] Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.
[2] Liman Yang, Jing Jin, Juhong Liu. Correlation of MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) with cervical cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 508-512.
[3] Panteleimon Mnimatidis, Abraham Pouliakis, George Valasoulis, George Michail, Aris Spathis, Christine Cottaridi, Niki Margari, Maria Kyrgiou, Maria Nasioutziki, Alexandros Daponte, Konstantinos Dinas, Evangelos Paraskevaidis, Ioannis Panayiotides, Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 545-555.
[4] Fengmei Wang , Huachun Luo , Huihua Cheng, Huijuan Huang , Zhichao Fu. Is 3D printing-gided three-dimensional brachytherapy suitable for cervical cancer: from one single research institute?[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 591-597.
[5] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta. Successful treatment of uterine cervical carcinoma with extensive vaginal lesions using laparoscopic surgery: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 629-633.
[6] Hikari Unno, Seiji Mabuchi, Isao Arai, Tomoko Wakasa, Seiichi Yamamasu. Development of lymphangiosarcoma after pelvic radiation therapy for uterine cervical cancer: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 326-331.
[7] H. Ishibashi, M. Miyamoto, T. Aoyama, H. Soyama, H. Matsuura, H. Iwahashi, M. Takano, K. Furuya. The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 386-390.
[8] L. Xu, H. Cai, N. Zhu, Bo Zheng. Interleukin-22 derived from cervical cancer-associated fibroblasts accelerates senescence of normal fibroblasts and promotes expression of tumorigenesis-related factors in HeLa cells[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 192-199.
[9] Hong Yan, Chunhua Zhang, Tingting Liu, Jianzhong Liu. Mifepristone regulates the multidrug resistance via miR-758/MEPE of Hela cell lines[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 214-220.
[10] K. Plagens–Rotman, M. Piskorz–Szymendera, B. PIĘTA. Lifestyle with particular emphasis on physical activity and genital carcinomas in women[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 233-239.
[11] B. Bárány, R. Póka. Nutritional assessment among patients with cervical cancer and controls[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 23-29.
[12] D. Kim, Y. Ki, W. Kim, D. Park, D. Suh, K. Kim, J. Lee, H. Jeon, J. Nam. Positive pelvic lymph node on [18F]-FDG PET is a prognostic factor in early-stage high-risk cervical cancer treated by radical hysterectomy and adjuvant chemoradiotherapy[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 42-47.
[13] H. Imafuku, Y. Ebina, K. Suzuki, S. Wakahashi, Y. Miyahara, K. Yoshida, H. Yamada. Definitive radiotherapy in elderly patients and patients with locally advanced cervical cancer with complications[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 60-64.
[14] Y. Murata, Y. Miyahara, K. Suzuki, S. Wakahashi, T. Sudo, S. Nagao, S. Yamaguchi, Y. Ebina, H. Yamada. Leukocytosis and thrombocytosis as prognostic factors for women with uterine cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 93-97.
[15] N. Habib, T. Dennis, G. Centini, L. Bresson, F. Narducci, E. Leblanc. Glassy cell carcinoma: is surgical treatment with preservation of the uterus a therapeutic option?[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 121-125.
No Suggested Reading articles found!